Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. - Test2 - elhamkhani - TriplyDB

Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.

Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33733758

about

Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog.

P2860

Q26766481-127B2BF4-4FD3-45B6-A963-FB434E209CE8 Q36485789-9C9B9F77-58F2-4C87-B1C3-D5D8E7E47889

P2860

Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer.

http://www.wikidata.org/entity/Q33733758

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@ast

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@en

type

label

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@ast

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@en

prefLabel

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@ast

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@en

P1433

Q33733758-6B47BBDA-77F8-4A00-8A3C-29DA80AA2B83

P1476

Q33733758-3F3FDD54-39A1-4148-BBB2-84065CA11475

P2093

Q33733758-0E5E759A-B48B-4C5F-B1EC-E8A685ABD077

Q33733758-959DC38B-2A33-427F-9536-9DEC4EA0C7BA

Q33733758-9DF44A34-4811-4462-B5B3-CFB28A25CB0D

Q33733758-BC3816C2-7AC2-4639-97D8-64CDE3AA2239

Q33733758-E420F903-9234-4194-88D1-4A80C057D3EE

Q33733758-F0A1A5CC-1299-467E-89EC-C59A6FC0EAB1

Q33733758-F9F953EB-7D92-41BE-BB32-F459522DA2AF

P2860

Q33733758-0026F8E9-6FE7-4EC7-9D80-C64FFB02AB7D

Q33733758-013BD0F2-9905-493C-9DB6-861C9B840CCB

Q33733758-03BD5A53-B217-4DC3-9009-2B5486545F50

Q33733758-121DFCFF-FD21-45BD-8CDE-BE91C5ED06A9

Q33733758-197BCCCF-52BB-4B82-AAAF-70B3B1F37277

Q33733758-1C843661-0472-42A2-B237-3011E3386DF4

Q33733758-1DE05AAD-3893-4D41-8115-973D239D0032

Q33733758-299C11DB-7A67-4219-A4FE-F24B2610012F

Q33733758-2C55DAE1-4771-4816-B96E-220200B065A9

Q33733758-38DF9808-B61F-4F5E-A03B-B57D808B47D1

P304

Q33733758-CAEC7BF4-5CEE-4E3E-82E5-458769908EE1

P31

Q33733758-3A0D72E3-4E59-42AC-8A5A-446CA53E65DF

P356

Q33733758-C049DED5-7EC5-4A1A-9C98-15838B705073

P433

Q33733758-48501EB4-B1D5-46B8-B117-97C43BAD2848

P478

Q33733758-E14453CB-FF5B-4FFA-B9C6-2C07A9DA6108

P577

Q33733758-EE3CB584-B7D2-4B8A-9852-1AF54AF8A901

P5875

Q33733758-B459CA3D-74F3-4B17-988C-18EA38E0BB8A

P698

Q33733758-4306F909-6F56-439B-BA1C-0764054D890F

P921

Q33733758-41B96F28-7B97-463E-87AA-1E4BB1A340F1

Q33733758-A2CE51E3-74F8-4B7F-9A5D-D939A2B05921

P932

Q33733758-E3F56090-4B3B-42A8-BFE6-5773B9128ED5

P356

P1433

Molecular and clinical oncology

P1476

Phase I trial of M2ES, a novel ...... in advanced pancreatic cancer.

@en

P2093

Fei Wu

http://www.w3.org/2001/XMLSchema#string

Ping Li

http://www.w3.org/2001/XMLSchema#string

Yan Fu

http://www.w3.org/2001/XMLSchema#string

Yang Chen

http://www.w3.org/2001/XMLSchema#string

Yiqi DU

http://www.w3.org/2001/XMLSchema#string

Yongzhang Luo

http://www.w3.org/2001/XMLSchema#string

Zhaoshen Li

http://www.w3.org/2001/XMLSchema#string

P2860

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.

Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.

P304

586-590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2014.271

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263208866

http://www.w3.org/2001/XMLSchema#string

P698

24940500

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4051555

http://www.w3.org/2001/XMLSchema#string